📊 HOWL Key Takeaways
Is Werewolf Therapeutics, Inc. (HOWL) a Good Investment?
Werewolf Therapeutics is a pre-commercial stage pharmaceutical company with zero revenue, negative operating cash flow of $10.6M annually, and a debt-to-equity ratio of 2.63x that cannot be serviced from operations. While the company maintains $46.5M in cash reserves (~4.5 years of runway at current burn rate), the combination of negative profitability, substantial debt burden, and lack of any commercial operations signals high financial distress risk.
Werewolf Therapeutics is pre-revenue with substantial operating losses and extremely negative returns, indicating no line-of-sight to self-sustainability. With ~$57M in cash against roughly ~$60M annual operating cash burn and -11.5x interest coverage, the balance sheet faces a short runway and leverage it cannot service from operations. Without a clear path to revenue or significant, non-dilutive funding, fundamentals skew toward dilution and potential solvency pressure.
Why Buy Werewolf Therapeutics, Inc. Stock? HOWL Key Strengths
- Adequate cash reserves ($46.5M) provide near-term operational runway
- Current liquidity ratio of 1.27x maintains minimal short-term solvency
- Nasdaq listing indicates past regulatory compliance for public markets
- Cash & equivalents of $57.05M supporting near‑term liquidity
- Current ratio of 1.62x and minimal capex needs
- EPS loss improved 18.4% YoY, suggesting some cost discipline
HOWL Stock Risks: Werewolf Therapeutics, Inc. Investment Risks
- Zero revenue indicates no commercial product traction or market validation
- Negative operating cash flow of $10.6M annually with no offsetting revenue
- Debt-to-equity ratio of 2.63x with negative interest coverage (-9.7x) creates unsustainable leverage
- High risk of equity dilution or debt restructuring as cash reserves deplete
- ROE of -110.9% and ROA of -23.3% demonstrate value destruction
- Pre-commercial stage with unproven clinical pipeline execution risk
- Persistent, large operating losses (~$60.7M) with no revenue
- High leverage (1.29x D/E) and negative interest coverage (-11.5x)
- Short cash runway relative to burn implying external financing/dilution risk
Key Metrics to Watch
- Cash burn rate and remaining runway (currently ~4.5 years at $10.6M annual burn)
- Clinical trial progress and regulatory milestones for pipeline programs
- Debt refinancing events and covenant compliance
- Operating expenses trend and cash conservation efforts
- Cash runway (cash & equivalents vs operating cash burn)
- Interest coverage
Werewolf Therapeutics, Inc. (HOWL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Werewolf Therapeutics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
HOWL Profit Margin, ROE & Profitability Analysis
HOWL vs Healthcare Sector: How Werewolf Therapeutics, Inc. Compares
How Werewolf Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Werewolf Therapeutics, Inc. Stock Overvalued? HOWL Valuation Analysis 2026
Based on fundamental analysis, Werewolf Therapeutics, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Werewolf Therapeutics, Inc. Balance Sheet: HOWL Debt, Cash & Liquidity
HOWL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Werewolf Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.63 indicates the company is currently unprofitable.
HOWL Revenue Growth, EPS Growth & YoY Performance
Werewolf Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
HOWL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Werewolf Therapeutics, Inc. (CIK: 0001785530)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 20, 2026 | 4 | xslF345X06/form4-05202026_100525.xml | View → |
| May 13, 2026 | 4 | xslF345X06/form4-05132026_080528.xml | View → |
| May 12, 2026 | 4 | xslF345X06/form4-05122026_110537.xml | View → |
| May 12, 2026 | 4 | xslF345X06/form4-05122026_100521.xml | View → |
| May 7, 2026 | 4 | xslF345X06/form4-05072026_100518.xml | View → |
❓ Frequently Asked Questions about HOWL
What is the AI rating for HOWL?
Werewolf Therapeutics, Inc. (HOWL) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are HOWL's key strengths?
Claude: Adequate cash reserves ($46.5M) provide near-term operational runway. Current liquidity ratio of 1.27x maintains minimal short-term solvency. ChatGPT: Cash & equivalents of $57.05M supporting near‑term liquidity. Current ratio of 1.62x and minimal capex needs.
What are the risks of investing in HOWL?
Claude: Zero revenue indicates no commercial product traction or market validation. Negative operating cash flow of $10.6M annually with no offsetting revenue. ChatGPT: Persistent, large operating losses (~$60.7M) with no revenue. High leverage (1.29x D/E) and negative interest coverage (-11.5x).
What is HOWL's revenue and growth?
Werewolf Therapeutics, Inc. reported revenue of N/A.
Does HOWL pay dividends?
Werewolf Therapeutics, Inc. does not currently pay dividends.
Where can I find HOWL SEC filings?
Official SEC filings for Werewolf Therapeutics, Inc. (CIK: 0001785530) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HOWL's EPS?
Werewolf Therapeutics, Inc. has a diluted EPS of $-0.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HOWL a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Werewolf Therapeutics, Inc. has a STRONG SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HOWL stock overvalued or undervalued?
Valuation metrics for HOWL: ROE of -110.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy HOWL stock in 2026?
Our dual AI analysis gives Werewolf Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HOWL's free cash flow?
Werewolf Therapeutics, Inc.'s operating cash flow is $-10.6M, with capital expenditures of $0.0.
How does HOWL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -110.9% (avg: 15%), current ratio 1.27 (avg: 2).
Is Werewolf Therapeutics, Inc. carrying too much debt?
HOWL has a debt-to-equity ratio of 2.63x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.27 suggests adequate short-term liquidity.